Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1 <sub>157–165</sub> by interacting with its central Met/Trp residues

22 Sept 2008

Abstract excerpt

Naturally acquired immune responses against human cancers often include CD8(+) T cells specific for the cancer testis antigen NY-ESO-1. Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients. We show that an important proportion of tumor-reactive T cells preferentially use TCR AV3S1/BV8S2 chains, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18809922
DOI: 10.1073/pnas.0807954105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1 <sub>157–165</sub> by interacting with its central Met/Trp residuesPMID 18809922Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.Semantic proximity Read ↗

Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificitySemantic proximity Read ↗

TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide–HLA ComplexSemantic proximity Read ↗

Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targetingSemantic proximity Read ↗

A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometrySemantic proximity Read ↗

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4Semantic proximity Read ↗

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell FunctionsSemantic proximity Read ↗

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1Semantic proximity Read ↗

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPα decoys with anti-tumor antibodies to augment macrophage phagocytosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.